KDDF, J&J Launch Joint Korea Diabetes R&D Program
This article was originally published in PharmAsia News
South Korea is continuing to step up open innovation initiatives with the multinational pharma sector, with the aim of accelerating global licensing out deals by domestic companies. In its latest efforts, the state-run Korea Drug Development Fund (KDDF) has tied up with J&J Innovation to develop and commercialize novel Korea-originated diabetes drugs for the global market.
You may also be interested in...
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.